Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

State Step Therapy Laws: Not All Are Created Equal

From the College  |  April 8, 2019

Step therapy reform has been a hot topic and major focus of the ACR’s advocacy activity in states this legislative session. Washington, Oregon, Wisconsin and Florida are all considering step therapy bills that stand good chance of passing this legislative year. Virginia and Georgia have already passed step therapy laws. When these two new laws take effect, 19 states will have step therapy laws on the books. However, not all step therapy laws are created equally.

What We Need
Although any progress on step therapy reform is typically better than the status quo, the ad hoc approach some states take creates barriers to additional reforms. Chief among these barriers is the fact that legislators are often reluctant to revisit matters they thought were fully resolved. For this reason, the ACR supports step therapy reform that includes the following:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Clear step therapy protocol guidelines that allow for overrides when:
    • A medication is contraindicated;
    • A patient has already failed the medication;
    • A patient is stable on their current medication;
  • A 24-hour decision window for emergency override requests;
  • A 72-hour decision window for non-emergency override requests; and
  • A clear and expedient appeals process.

What We Have
Many states enact laws that include only some of these provisions. Practitioners in states that do not have a comprehensive step therapy law often report that there has been no improvement in step therapy override processes or the paperwork associated with getting an override approved. California is perhaps the best example of this phenomenon.

The ACR has had substantial feedback from California physicians indicating the paperwork required for step therapy override requests has not been reduced. The enforcement mechanism to punish violators of the statute is also inadequate. California is not alone in problematic approaches to step therapy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ohio passed step therapy reform late last year. This bill was widely championed as a substantial late session win. Although the bill contains much to praise, one section of problematic language in the step therapy override exceptions has started to show up in step therapy bills in other states: Patients who are stable on their current medications can remain on them, but this exception allows insurers to require patients try a pharmaceutical alternative from the FDA’s orange or purple book before the insurer is required to cover the patient’s medication. This bill will not go into effect until January 2020, so the jury is still out on how this loophole will affect patients, but the impacts could be significant and disruptive.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & Advocacy Tagged with:step therapystep therapy reform legislation

Related Articles

    Step Therapy Legislation in the States: Navigating a Varied & Complex System

    July 17, 2019

    As the practice of step therapy grows more pervasive throughout the insurance industry, the protocols become increasingly confusing to navigate. Steps vary from insurer to insurer based on plan type, and formulary differences are too often based on economic incentives rather than outcome-based medicine. Patients are often left hanging in the balance while physicians’ offices…

    The Georgia Society of Rheumatology in Focus

    June 15, 2020

    As president of the Georgia Society of Rheumatology (GSR), Wambui Machua, MD, a rheumatologist with Piedmont Physicians Rheumatology, Atlanta, oversees a membership of 90 rheumatologists, six orthopedists, two nurses, 85 physician assistants and 27 fellows and residents. According to Dr. Machua, the GSR, founded in 1967, continues to pursue its original mission of providing educational…

    The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy

    August 10, 2016

    A majority of state legislatures have concluded their work for 2016. The ACR’s state advocacy efforts continued to focus on policy benefiting rheumatologists and patients alike. The two dominant issues this year were biosimilar substitution and step therapy. Biosimilar Substitution Biosimilar substitution remains the most prevalent issue throughout the states. The ACR continues to monitor…

    Spring Review of 2021 State Legislative Progress

    May 7, 2021

    Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences